With Appointment of Genetics Expert as R&D Head, Teva May Be Eyeing Personalized Rx Market | GenomeWeb

The appointment of genetics expert Michael Hayden as Teva Pharmaceutical's president of global R&D has some industry observers speculating that the generic drug giant is eyeing the personalized medicine market as part of its future growth strategy.

Hayden, who will also serve as the company's chief scientific officer, is professor of medical genetics at the University of British Columbia and Canada Research Chair in human genetics and molecular medicine. He founded the Center of Molecular Medicine and Therapeutics at the university.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.